Biologica Launches Hormone-Stage Supplements for Women, Backed by $7M and 1,000-Person Study
WELLNESS

Biologica Launches Hormone-Stage Supplements for Women, Backed by $7M and 1,000-Person Study

By Yuna · · Yahoo Finance
KO | EN

A woman’s body at 25 is not the same as at 42, and neither is her hormonal environment. Yet most supplements on the market are designed as one-size-fits-all solutions, indifferent to where a woman actually is in her life. Biologica was built around that gap.

The brand officially launched on December 9, 2025, through biologica.com. Its founders, Liz Zwillinger and Joey Zwillinger, designed it around three distinct hormonal stages rather than a single universal formula. Joey is best known as co-founder of Allbirds, the sustainable footwear brand. This time, he and his wife are focused on women’s health.

$7 Million in Seed Funding, and the Investors Behind It

Biologica raised $7 million in seed funding before launch. The round was led by Addition, with participation from Hawktail (led by Michael Polansky), Greycroft (which counts Katherine Power among its partners), and True Beauty Ventures. Good Friends, the firm founded by the co-founders of Warby Parker, Harry’s, and Flamingo, also joined the round. Bestselling author Gabrielle Bernstein and Katherine Schwarzenegger Pratt are among the individual investors.

The lineup signals something beyond a consumer brand. It positions Biologica at the intersection of wellness, women’s health, and science-backed nutrition, which is precisely where investor attention has been building.

Research Before the Product

Before developing a single formula, Biologica conducted a health study across 1,000 women. The goal was to understand what symptoms women actually experience at different hormonal stages, not what products might sell well. The scientific advisory board includes OB/GYNs, a breast surgical oncologist, and a naturopathic doctor, each involved in actual product design rather than just lending their names.

From that research came three lines.

Primary is for women aged 18 to 45. It targets mood regulation, skin health, and PMS symptoms, with a formulation built around the hormonal fluctuations of the menstrual cycle.

Midlife is for women aged 40 to 55, the perimenopause transition years. It addresses sleep disruption, irritability, and brain fog, three of the most commonly reported complaints during this stage.

Postmenopause is for women 50 and older. With estrogen levels permanently reduced, the formulation shifts focus to cognition, bone density, cardiovascular health, and cellular protection.

Why 28mg of Saffron Matters

One of the most clinically specific ingredients in the lineup is Affron, a standardized saffron extract included at 28mg, the dose used in published clinical trials. Saffron is familiar as a spice, but at certain concentrations it influences serotonin and dopamine pathways in ways that multiple studies have connected to improved mood and reduced irritability.

The 28mg figure matters because it reflects the amount shown to produce measurable effects in clinical research. Many supplements on the market either do not disclose their saffron content or include amounts too small to match the doses studied.

Effervescent Drinks, Recyclable Tins

Rather than capsules or tablets, Biologica chose an effervescent format that dissolves in water. The format was selected for both bioavailability and the daily experience of taking it. Packaging comes in recyclable tin cans, a nod to the sustainability focus that defined Allbirds from the start.

Pricing is $70 per tin (around $2 per day), with a subscription option at $59 per month.

A Market Catching Up to Women’s Actual Lives

Biologica’s launch reflects a broader shift in women’s health supplements. The category has long been anchored to two poles: prenatal support and menopause symptom relief. The space in between, the years when a woman’s hormonal environment is actively shifting but not yet categorized as a clinical phase, has received far less attention.

The brand’s framework, three lines mapped to distinct life stages and informed by research with 1,000 real women, offers a different starting point: not what you should take, but where you are right now.